click below
click below
Normal Size Small Size show me how
Platelet Aggregate -
USMLE Step 1
Drug | MOA & ADRs |
---|---|
Aspirin | MOA: - COX (blocks TXA2 synthesis that + platelets [IP3, DAG] -> degranulation, effectively decreases recurrence of MI, decreases mortality in post-MI pts; ADRs: effects are irreversible |
Sulfinpyrazone | MOA: - degranulation (5-HT, ADP), prolongs platelet survival; ADRs: uricosuric agent that blocks the proximal tubule resorption of uric acid |
Dipyridamole (Persantine) | MOA: phosphodiesterase inhibitor that increases cAMP to inhibit degranulation, this antagonizes platelet stickiness & thus decreases adhesiveness to thrombogenic surfaces |
Clopidogrel | MOA: - ADP mediated platelet aggregation process = powerful, those who recieve stents are Rx this drug, common for prophylaxis of MI and cerebrovascular accident for pts at significant risk |
Eptifibatide | MOA: glycoprotein 2b3a antagonist that block receptor on platelets that nmlly act 2 bind platelets together, used 2 minimize risk 4 recurrent MI, recurrent unstable angina, decrease risk of stent reocclusion during coronary artery angioplasty, IV drip use |
Abciximab | MOA: glycoprotein 2b3a antagonist that block receptor on platelets that nmlly act 2 bind platelets together, used 2 minimize risk 4 recurrent MI, recurrent unstable angina, decrease risk of stent reocclusion during coronary artery angioplasty, IV drip use |
Tirofiban | MOA: glycoprotein 2b3a antagonist that block receptor on platelets that nmlly act 2 bind platelets together, used 2 minimize risk 4 recurrent MI, recurrent unstable angina, decrease risk of stent reocclusion during coronary artery angioplasty, IV drip use |